Wolverine Legal Status, FDA 503A Category, and Compounding Access

Wolverine legal status: access is under active FDA review

The Wolverine legal status story has real momentum behind it. Access to the blend's two components is under active FDA review, and it may expand in 2026: the FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet on July 23-24, 2026 to discuss BPC-157 and TB-500 as candidates for the 503A Bulks List ^[11]. That is the live, citable fact pointing forward — a scheduled evaluation of exactly these peptides.

Momentum is not a decision, though, and this review will not pretend otherwise. As of the most recent action confirmable from the FDA, both constituents sit in 503A Category 2 — bulk drug substances that may present significant safety risks — which currently restricts their use in compounding ^[9][10]. The July meeting is a step in evaluation, not a listing; a PCAC discussion is advisory, and no outcome should be assumed or dated ^[10][11].

So the honest framing is forward-leaning and hedged at once: the door is being looked at, not opened. What follows is the present-tense record, sourced to the FDA, with the scheduled review marked as a scheduled review and nothing more.

The current FDA 503A status of Wolverine's components

U.S. drug compounding is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally under a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulk drug substances list ^[10].

Under the FDA's interim policy, nominated substances were sorted into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation; Category 2 substances are those the FDA identified as raising significant safety risks, and they are not afforded that discretion — the FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[10].

Both of Wolverine's components are in Category 2. Effective with the FDA's September 29, 2023 update to the nominated-substances list, the FDA placed BPC-157 in Category 2, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization ^[9]. In the same update, the FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in Category 2, citing potential immunogenicity for certain routes and a lack of important safety information; the FDA's own list entry establishes that TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 ^[9]. Neither constituent is an FDA-approved drug, and there is no component carve-out — both are Category 2 ^[9].

Both components are on one scheduled review

There is no split between the two peptides at the regulatory level. Both BPC-157 and TB-500 appear on the published agenda of the July 23-24, 2026 PCAC meeting, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[11]. The agenda entries cover the free-base and acetate forms of each.

That single scheduled review is the entire forward-looking record this site will stand behind. Being discussed by PCAC is a step in evaluation — informed input that feeds FDA rulemaking — not a final listing decision ^[10][11]. The outcome is unknown, and this review states no reclassification as done, dated, or certain.

The practical reading for now: both of Wolverine's constituents are Category 2 today, both are under one scheduled review, and the status that governs access is the present-tense one, not the one the July meeting might produce ^[9][11].

How legally compounded peptide access works

In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[10]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility ^[10].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is a route to a licensed-prescriber consultation, not a separate legal status: telehealth does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[10].

The ingredient-eligibility caveat is the binding one here. A compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules — a USP/NF monograph, a component of an approved drug, or a place on the applicable bulks list. Ingredients the FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[9][10]. This page is general information about the regulatory landscape; it is not medical or legal advice, and it does not name or endorse any pharmacy, clinic, or provider.

Doping status

Beyond the compounding question, both constituents are prohibited in sport. The World Anti-Doping Agency lists BPC-157 under its S0 non-approved-substances category and lists TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories; the blend is banned for athletes subject to the Code. The TB-500 fragment was in fact synthesized and characterized as a doping-control reference, which fixes its identity for analytical testing ^[5].

Is Wolverine legal?

Neither constituent is an FDA-approved drug, and the blend has no approved therapeutic indication. As of the most recent confirmable FDA action, both BPC-157 and the TB-500 (LKKTETQ) fragment are 503A Category 2 bulk substances — flagged for significant safety risks — which restricts their use in pharmacy compounding ^[9][10]. Both are also prohibited in sport under the World Anti-Doping Code. This is general information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

BPC-157's compounding access is currently restricted. Effective with the FDA's September 29, 2023 list update, BPC-157 is a 503A Category 2 bulk substance, which is not covered by the FDA's enforcement-discretion policy for compounding ^[9]. BPC-157 is on the July 23-24, 2026 PCAC agenda as a candidate for the 503A Bulks List, but that is a scheduled review under active evaluation, not a decision or a change in current status ^[11].

What is the FDA 503A status of Wolverine?

Both of Wolverine's components are 503A Category 2: effective with the FDA's September 29, 2023 update, BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" were placed in Category 2 as bulk substances that may present significant safety risks, restricting compounding access ^[9]. Both are on the July 23-24, 2026 PCAC agenda as candidates for the bulks list — a scheduled review, not a listing decision ^[11].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and the blend has no approved therapeutic indication. Effective with the FDA's September 29, 2023 update, both BPC-157 and the TB-500 (LKKTETQ) fragment are 503A Category 2 bulk substances flagged for significant safety risks ^[9]. Both constituents are prohibited by WADA — BPC-157 under S0, and TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories ^[5].